NPY rs16148: What Your Genotype Means
The rs16148 variant is a single-nucleotide polymorphism located in the promoter region of the neuropeptide Y (NPY) gene on chromosome 7. Research has linked this variant to differences in transcriptional activity, which may modulate circulating and central levels of neuropeptide Y. Because neuropeptide Y plays an important role in buffering the brain against stress, rs16148 has been investigated for its relationship with neural stress resilience and autonomic nervous system activity.
What each genotype means
Lower baseline NPY expression
You carry two copies of the C allele in the NPY promoter region, which has been linked in laboratory studies to lower neuropeptide Y gene expression and circulating levels. Research suggests this profile is statistically correlated with heightened amygdala reactivity to threats and altered autonomic stress response, although findings vary across ancestries and evidence remains limited. These genetic tendencies reflect broad statistical patterns and do not determine how you handle everyday stress or clinical health outcomes.
Found in approximately 25% to 30% of individuals across global populations, including European and East Asian cohorts.
Intermediate NPY expression
You carry one copy of the C allele and one copy of the T allele in the NPY promoter. This genotype is generally associated with intermediate levels of neuropeptide Y expression and typical physiological stress resilience. Given that evidence linking this variant to psychological or autonomic stress outcomes is limited and mixed, having this genotype simply places you near the population average.
Carried by approximately 45% to 50% of people globally, making it the most frequent genotype across major ancestral groups.
Higher baseline NPY expression
You carry two copies of the T allele, which has been correlated with higher expression of neuropeptide Y in experimental models. In observational studies, higher NPY levels have been linked to greater autonomic stress resilience, such as preserved cardiac vagal outflow under stress, though evidence across broader clinical outcomes remains limited and non-diagnostic. This profile reflects an average biological variation rather than a definitive guarantee of stress hardiness.
Observed in roughly 20% to 25% of individuals globally, with similar frequencies reported across European and Asian populations.
Genomic Location and the NPY Promoter
The single-nucleotide polymorphism rs16148 sits within the regulatory promoter region upstream of the human NPY gene, situated on the short arm of chromosome 7 at band 7p15.3. Promoter regions contain specific sequence motifs where transcription factors, RNA polymerase complexes, and structural proteins dock to initiate gene transcription. Because of its specific position in the regulatory sequence, rs16148—often studied alongside tightly linked neighboring promoter variants like rs16147—can alter local chromatin architecture and DNA-protein binding dynamics. Molecular assays demonstrate that nucleotide substitutions across this regulatory cluster change transcription factor affinity, leading to measurable differences in basal messenger RNA output. Rather than altering the structure of the encoded peptide, rs16148 acts quantitatively by adjusting how readily the cell produces neuropeptide Y transcripts in response to physiological cues.
Biological Role of Neuropeptide Y
Neuropeptide Y is a 36-amino-acid peptide neurotransmitter widely distributed throughout both the central and peripheral nervous systems. In the brain, NPY acts as a natural anxiolytic and counter-regulatory buffer against the physiological effects of stress, counteracting corticotropin-releasing factor in emotional processing regions such as the amygdala, hippocampus, and prefrontal cortex. In the periphery, NPY is co-released with norepinephrine from sympathetic nerve terminals, influencing vasoconstriction, blood pressure, metabolic homeostasis, and cardiovascular adaptation. Because NPY coordinates both central emotional responses and peripheral autonomic balance, individual differences in baseline NPY synthesis can influence how effectively the body adapts to acute tension and chronic psychological distress. Higher endogenous NPY signaling generally promotes rapid autonomic recovery, robust parasympathetic vagal reactivation, and psychological resilience during demanding environmental conditions.
Research Associations and Evidence Strength
Scientific interest in rs16148 stems from candidate-gene and neuroimaging studies examining emotional reactivity, anxiety traits, and autonomic stress responses. Several investigations have observed that alleles associated with altered promoter efficiency correlate with variations in emotional processing within the amygdala and differences in heart rate variability during stress testing. However, the overall clinical and epidemiological evidence for rs16148 remains limited. Many early associations were derived from modest candidate-gene cohorts or haplotype analyses that combined multiple promoter sites, and large-scale genome-wide association studies (GWAS) frequently fail to replicate single-locus candidate findings with statistical significance. The genetic influence of rs16148 on complex phenotypes like stress coping is subtle, highly polygenic, and heavily influenced by environmental context, such as early-life adversity and ongoing lifestyle stressors.
Population Frequency and Allelic Distribution
Data from large-scale reference databases such as the Genome Aggregation Database (gnomAD) indicate that rs16148 is a balanced, highly common polymorphism worldwide. The minor allele frequency hovers near 0.48 across global populations, meaning that both alternative alleles are extensively represented across diverse ancestral backgrounds. Because both alleles are so common, heterozygous and homozygous genotypes are widely distributed among healthy individuals without causing clinical disorders or rare pathological phenotypes. Regional differences in frequency between continental ancestries are relatively minor compared to rare pathogenic variants, reflecting an ancient polymorphic balance that has persisted across human evolutionary history. Consequently, having any specific genotype at rs16148 is a typical, normal variation within the human genome.
Interpretation and Practical Considerations
Understanding your rs16148 genotype provides educational insight into baseline neurochemical signaling pathways, but it cannot diagnose an anxiety disorder, predict mental health outcomes, or forecast clinical stress tolerance. Complex psychological traits and physiological responses to stress arise from thousands of small-effect genetic variants interacting dynamically with personal history, social support, sleep, exercise, and mental health practices. No single variant dictates emotional resilience or cardiovascular risk. Furthermore, while NPY pathways interact with various neurotransmitter systems, rs16148 does not have established clinical pharmacogenomic guidelines from bodies such as CPIC or PharmGKB. This information should not be used to alter medications or psychiatric treatments. Any health questions or concerns regarding chronic stress and emotional well-being should always be discussed with a qualified healthcare provider.
How common is this variant?
The rs16148 variant is common across all major continental populations, exhibiting a global minor allele frequency of approximately 0.48 in gnomAD. Because both alleles are nearly equally balanced, heterozygous and homozygous genotypes are widely distributed among healthy populations worldwide.
Frequently asked questions
Can testing rs16148 tell me if I have high stress resilience?
No. While research associates NPY promoter variations with subtle differences in autonomic tone and brain reactivity, resilience is a complex trait determined by thousands of genetic markers, environment, life experience, and personal coping strategies.
Does my rs16148 genotype cause anxiety or depression?
No. The rs16148 variant is a benign, common polymorphism present in billions of healthy individuals. It is not a diagnostic marker or a direct cause of any psychiatric illness.
Should I adjust any medications based on my rs16148 results?
No. The rs16148 variant does not have actionable pharmacogenomic guidelines from authoritative bodies like CPIC or PharmGKB. Never adjust prescriptions, psychiatric therapies, or dosing without consulting your doctor or pharmacist.
What is the biological function of the NPY gene?
The NPY gene encodes neuropeptide Y, an important chemical messenger in the central and autonomic nervous systems that regulates emotional responses, blood vessel tone, hunger, and stress counter-regulation.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16148?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in NPY
Functional promoter polymorphism in neuropeptide Y influencing expression levels, stress-coping mechanisms, and emotional reactivity during acute stress tasks.
Regulatory neuropeptide Y promoter polymorphism associated with blunted stress-evoked neuropeptide Y release and increased vulnerability to stress-induced pathology.